Denbufylline

Denbufylline Struktur
57076-71-8
CAS-Nr.
57076-71-8
Englisch Name:
Denbufylline
Synonyma:
brl30892;DENBUFYLLINE;1,3-DI-N-BUTYL-7-(2'-OXOPROPYL)XANTHINE;7-Acetonyl-1,3-dibutyl-3,7-dihydro-1H-purine-2,6-dione;3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-6-dione;3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-2,6-dione;1,3-Dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione;1H-Purine-2,6-dione, 1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-
CBNumber:
CB1704523
Summenformel:
C16H24N4O3
Molgewicht:
320.39
MOL-Datei:
57076-71-8.mol

Denbufylline Eigenschaften

Schmelzpunkt:
98-100°C
Siedepunkt:
514.8±56.0 °C(Predicted)
Dichte
1.23±0.1 g/cm3(Predicted)
storage temp. 
Refrigerator
Löslichkeit
DMSO, Methanol
Aggregatzustand
Solid
pka
-0.17±0.70(Predicted)
Farbe
Off-White to Pale Beige
CAS Datenbank
57076-71-8

Sicherheit

Denbufylline Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Denbufylline, a xanthine derivative and PDE4 inhibitor, has effects such as vasodilatation of cerebral vessels (Willette et al., 1997) and potent activation of the hypothalamic–pituitary–adrenal axis. PDE4 is one of the cyclic adenosine monophosphate (cAMP)–specic phosphodiesterases whose tissue distribution is important in pathologies related to the central nervous and immune systems. In experimental animals, denbufylline increases adrenocorticotropic hormone (ACTH), circulating corticosterone, luteinizing hormone, corticotrophin-releasing hormone, and cAMP content of the hypothalamic tissue, but is without effect on arginine vasopressin (Kumari et al., 1997). Treves and Korczyn (1999) studied patients with AD, mixed dementia, and VaD treated with denbufylline. No signicant differences were found in comparison with placebo for the treatment of AD or VaD, although patients who received denbufylline tended to improve their cognitive scores.

Chemische Eigenschaften

White Solid

Verwenden

A cell permeable xanthine derivatvie that acts as a selective inhibitor of phosphodiesterase IV (PDE IV). Possesses bronchodilatory properties. Displays negative inotropic effect by acting on a verapamil-sensitive site of the calcium channel in guinea pig ventricle apaillary muscle independently of its PDE inhibitory activity.

Denbufylline Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Denbufylline Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 31)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
J & K SCIENTIFIC LTD. 010-82848833 400-666-7788
jkinfo@jkchemical.com China 94717 76
Chemsky(shanghai)International Co.,Ltd. 021-50135380
shchemsky@sina.com China 32344 50
Shanghai TaoSu Biochemical Technology Co., Ltd. 021-33632979
info@tsbiochem.com China 8073 58
Shenzhen Polymeri Biochemical Technology Co., Ltd. +86-400-002-6226 13028896684
sales@rrkchem.com China 56057 58
Foshan Treasure Biotechnology Co., Ltd 0757-85921206 18520245316
2329783215@qq.com China 12664 58
Changzhou Bojia Biomedical Technology Co., Ltd. 2122619822
czbjpharma@126.com China 18488 58
Carbosynth --
sales@carbosynth.com United Kingdom 6018 58

57076-71-8()Verwandte Suche:


  • 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-2,6-dione
  • 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-6-dione
  • brl30892
  • 1,3-DI-N-BUTYL-7-(2'-OXOPROPYL)XANTHINE
  • DENBUFYLLINE
  • 1,3-Dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione
  • 7-Acetonyl-1,3-dibutyl-3,7-dihydro-1H-purine-2,6-dione
  • 1H-Purine-2,6-dione, 1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-
  • 57076-71-8
  • C16H24N4O3
  • Inhibitors
Copyright 2019 © ChemicalBook. All rights reserved